Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 3
1992 3
1993 1
1994 4
1995 4
1996 4
1997 5
1998 5
1999 3
2000 2
2001 6
2002 7
2003 8
2004 12
2005 11
2006 14
2007 14
2008 13
2009 18
2010 26
2011 25
2012 23
2013 33
2014 28
2015 25
2016 23
2017 28
2018 26
2019 23
2020 26
2021 39
2022 22
2023 18
2024 36
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

509 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for masumori n
Search for Masamori N instead (2 results)
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Rini BI, et al. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Masumori N. Masumori N. Int J Urol. 2015 Jun;22(6):589. doi: 10.1111/iju.12765. Epub 2015 Mar 31. Int J Urol. 2015. PMID: 25827235 No abstract available.
JCS/JCC/JACR/JATS 2024 Guideline on Cardiovascular Practice With Consideration for Diversity, Equity, and Inclusion.
Tsukada YT, Aoki-Kamiya C, Mizuno A, Nakayama A, Ide T, Aoyama R, Honye J, Hoshina K, Ikegame T, Inoue K, Bando YK, Kataoka M, Kondo N, Maemura K, Makaya M, Masumori N, Mito A, Miyauchi M, Miyazaki A, Nakano Y, Nakao YM, Nakatsuka M, Nakayama T, Oginosawa Y, Ohba N, Otsuka M, Okaniwa H, Saito A, Saito K, Sakata Y, Harada-Shiba M, Soejima K, Takahashi S, Takahashi T, Tanaka T, Wada Y, Watanabe Y, Yano Y, Yoshida M, Yoshikawa T, Yoshimatsu J, Abe T, Dai Z, Endo A, Fukuda-Doi M, Ito-Hagiwara K, Harima A, Hirakawa K, Hosokawa K, Iizuka G, Ikeda S, Ishii N, Izawa KP, Kagiyama N, Umeda-Kameyama Y, Kanki S, Kato K, Komuro A, Konagai N, Konishi Y, Nishizaki F, Noma S, Norimatsu T, Numao Y, Oishi S, Okubo K, Ohmori T, Otaki Y, Shibata T, Shibuya J, Shimbo M, Shiomura R, Sugiyama K, Suzuki T, Tajima E, Tsukihashi A, Yasui H, Amano K, Kohsaka S, Minamino T, Nagai R, Setoguchi S, Terada K, Yumino D, Tomoike H; Japanese Circulation Society Joint Working Group. Tsukada YT, et al. Among authors: masumori n. Circ J. 2025 Apr 25;89(5):658-739. doi: 10.1253/circj.CJ-23-0890. Epub 2025 Mar 20. Circ J. 2025. PMID: 39971310 Free article. No abstract available.
Management of apalutamide-induced rash with focus on early peaks.
Hashimoto K, Shindo T, Nishida S, Kobayashi K, Tanaka T, Masumori N. Hashimoto K, et al. Among authors: masumori n. Int J Urol. 2025 Jan;32(1):113-115. doi: 10.1111/iju.15587. Epub 2024 Oct 21. Int J Urol. 2025. PMID: 39428952 No abstract available.
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg JE, Mamtani R, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Sridhar SS, Pappot H, Gurney H, Bedke J, van der Heijden MS, Galli L, Keam B, Masumori N, Meran J, O'Donnell PH, Park SH, Grande E, Sengeløv L, Uemura H, Skaltsa K, Campbell M, Matsangou M, Wu C, Hepp Z, McKay C, Powles T, Petrylak DP. Rosenberg JE, et al. Among authors: masumori n. Eur Urol. 2024 Jun;85(6):574-585. doi: 10.1016/j.eururo.2024.01.007. Epub 2024 Feb 28. Eur Urol. 2024. PMID: 38418343 Free PMC article. Clinical Trial.
509 results